Group Discussion Contest : Drug Discovery and Indian Pharma Industry
" Real progress depends on new observations which may turn into discoveries if they are made by imaginative minds"
Opening Note for Discussion : by Dr. V. Addepalli
A Roadmap to New Drug Discovery
The new millennium has ushered in an era of science that will revolutionize a great majority of our day-to-day activities and life style. Drug research has contributed to the progress of medicine during recent times but the its often debated whether the drug discovery is chemistry driven, technology driven, biology driven, or rather innovative driven, which is core and necessity of any new process. New drug discovery and development is associated with big risks and big rewards. The main goal is to optimize efficacy of the new drug i.e. lead optimisation by removing the bottlenecks of ADMET, Toxicity along with patient and market compliance. The reasons for the low numbers of successful drugs against novel targets are controversial, although it is undoubtedly related to their higher attrition rate during development, particularly from issues related to failures of on target biological hypotheses and on- and off- target safety concerns. To address these problems, there has been a recent emphasis on the ‘front-loading’ of research to tackle these issues at an earlier stage in the dug discovery pathway. The advent of molecular pharmacology and genetic science is having a deep impact on drug discovery. Increasing interventions of genomic sciences, rapid DNA sequencing, combinatorial chemistry, cell based assays and automated high-throughput screening has led to a ‘new’ concept of drug discovery. In this new concept, the critical course between chemists and pharmacologists and the quality of scientific reasoning are dominated by ‘omics’ technologies (transcriptomics, proteomics and metabonomics). The challenge ahead is to effectively translate the huge discovery potential of the genome into real products . Inspite of increased spending on pharmaceutical research and development, the number of new drug approvals has remained relatively constant at 30 per year (new molecule entities). Surprisingly (or expectedly?) the completion of the human genome project have failed to produce the expected flood of compounds targeting new, or as often termed ‘novel’, targets. Taking into consideration the classical drug discovery process and present day new drug discovery process which has been either multi targeted or selected molecule generation, there has been a paradigm shift but the question that needs to be answered is that how far we have reached? And are we really meeting the unmet needs? How can we face challenges of drug discovery process and yet making it cost effective process? How far we can reduce the bottlenecks? See questions to be answered in your discussion . Remember
Are you ready ? Please post your opinion (after login ) here before Jan 31st,2010: http://www.pharmainfo.net/comment/reply/135794#comment-form